Lindbrook Capital LLC Has $196,000 Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Lindbrook Capital LLC grew its stake in DexCom, Inc. (NASDAQ:DXCM) by 20.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,583 shares of the medical device company’s stock after purchasing an additional 268 shares during the period. Lindbrook Capital LLC’s holdings in DexCom were worth $196,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of DXCM. abrdn plc raised its stake in DexCom by 21.1% during the fourth quarter. abrdn plc now owns 380,535 shares of the medical device company’s stock worth $47,221,000 after acquiring an additional 66,348 shares in the last quarter. Hunter Associates Investment Management LLC acquired a new stake in shares of DexCom during the 4th quarter worth about $217,000. Kornitzer Capital Management Inc. KS bought a new position in DexCom during the 4th quarter valued at about $9,961,000. Greenleaf Trust boosted its position in DexCom by 37.9% in the fourth quarter. Greenleaf Trust now owns 6,411 shares of the medical device company’s stock valued at $796,000 after buying an additional 1,761 shares in the last quarter. Finally, Knights of Columbus Asset Advisors LLC boosted its position in DexCom by 3.1% in the fourth quarter. Knights of Columbus Asset Advisors LLC now owns 10,407 shares of the medical device company’s stock valued at $1,291,000 after buying an additional 310 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on DXCM. Citigroup lifted their target price on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Raymond James increased their target price on DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 23rd. Royal Bank of Canada started coverage on DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target for the company. Finally, UBS Group increased their price objective on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Two equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $141.40.

DexCom Stock Up 0.6 %

NASDAQ:DXCM opened at $131.52 on Tuesday. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18. DexCom, Inc. has a 12-month low of $74.75 and a 12-month high of $142.00. The stock’s fifty day simple moving average is $129.81 and its 200-day simple moving average is $117.38. The firm has a market capitalization of $50.70 billion, a P/E ratio of 100.40, a P/E/G ratio of 2.25 and a beta of 1.20.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. The firm had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.02 billion. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The company’s revenue was up 26.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.34 earnings per share. Equities research analysts expect that DexCom, Inc. will post 1.76 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the sale, the executive vice president now owns 42,377 shares in the company, valued at approximately $5,839,974.37. The transaction was disclosed in a filing with the SEC, which is available through this link. In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of DexCom stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total value of $10,803,093.52. Following the transaction, the chief executive officer now owns 333,526 shares of the company’s stock, valued at $44,479,027.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the sale, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The disclosure for this sale can be found here. Over the last three months, insiders have sold 189,375 shares of company stock worth $25,530,859. Company insiders own 0.41% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.